Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6B2P

Dual Inhibition of the Essential Protein Kinases A and B in Mycobacterium tuberculosis

Summary for 6B2P
Entry DOI10.2210/pdb6b2p/pdb
DescriptorSerine/threonine-protein kinase PknB, 5-{5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}thiophene-2-sulfonamide (2 entities in total)
Functional Keywordskinase, drug design, tuberculosis, transferase-inhibitor complex, transferase/inhibitor
Biological sourceMycobacterium tuberculosis
Cellular locationCell membrane ; Single-pass membrane protein : P9WI80
Total number of polymer chains1
Total formula weight30684.03
Authors
Zuccola, H.J. (deposition date: 2017-09-20, release date: 2018-02-14, Last modification date: 2024-03-13)
Primary citationWang, T.,Bemis, G.,Hanzelka, B.,Zuccola, H.,Wynn, M.,Moody, C.S.,Green, J.,Locher, C.,Liu, A.,Gao, H.,Xu, Y.,Wang, S.,Wang, J.,Bennani, Y.L.,Thomson, J.A.,Muh, U.
Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions.
ACS Med Chem Lett, 8:1224-1229, 2017
Cited by
PubMed Abstract: Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in . Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery. This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases. Compounds achieved potent inhibition ( ≈ 5 nM) of both PknA and PknB. A binding pocket unique to mycobacterial kinases was identified. Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases. Reducing lipophilicity improved antimycobacterial activity with the most potent compounds achieving minimum inhibitory concentrations ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of .
PubMed: 29259738
DOI: 10.1021/acsmedchemlett.7b00239
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.01 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon